I've been deep in two books that, together, make one of the more compelling arguments in integrative oncology today: that cancer may be better understood as a metabolic disease than a purely genetic one. The foundational research comes from Dr. Thomas Seyfried, a Boston College professor and author of Cancer as a Metabolic Disease, and the clinical, practical framework built on that foundation comes from Dr. Nasha Winters and Jess Higgins Kelley, in their book The Metabolic Approach to Cancer. I want to walk through the core theory, and then spend real time on what I think is the most useful part of Winters' work: the concept of "terrain," and what it actually means to fix it.
The Core Theory: Cancer as a Metabolic Disease
For most of the last century, cancer research has been dominated by the somatic mutation theory — the idea that cancer originates from an accumulation of genetic mutations in a cell's nucleus, which then drive uncontrolled growth. Seyfried's work argues, controversially but with real research behind it, that this puts the emphasis in the wrong place. He points back to Otto Warburg's early-20th-century discovery that cancer cells overwhelmingly rely on fermentation (glycolysis) for energy, even when oxygen is plentiful — a phenomenon now called the Warburg effect, which we've actually touched on before in this series when we discussed insulin and pancreatic cancer.
Seyfried's argument extends Warburg's observation further: he proposes that this metabolic dysfunction, rooted specifically in damaged mitochondria, isn't just a symptom of cancer — it may be the actual origin of it. In his framework, genetic mutations are downstream consequences of mitochondrial dysfunction, not the root cause. This is a genuinely significant departure from mainstream oncology's primary framework, and it remains a contested, minority position within cancer research — respected by some, firmly disputed by others. It has not displaced somatic mutation theory as the dominant model, and I think it's important to say that plainly rather than present it as settled science.
Where This Gets Clinically Practical: Winters and "The Terrain"
It's worth knowing that Winters brings more than a clinical or academic lens to this work — she has spoken publicly about her own diagnosis with advanced ovarian cancer in her twenties, and about using an integrative, terrain-focused approach alongside conventional treatment as part of her own path through it. That personal history is part of what shaped her clinical framework and, I think, part of why the book resonates with so many patients looking for something beyond a purely pharmaceutical approach.
This is where Winters and Higgins Kelley's book takes Seyfried's more academic, mechanistic argument and turns it into something a patient or practitioner can actually work with. Their central concept is the terrain — borrowing from a much older debate in medical history between Louis Pasteur (germ theory: pathogens are the primary cause of disease) and Antoine Béchamp (terrain theory: the internal environment determines whether a pathogen, or in this case a cancerous process, can take hold and thrive).
Winters' argument is that focusing exclusively on killing cancer cells (the pathogen-focused approach) without addressing the underlying terrain that allowed cancer to develop in the first place is treating half the problem. Her framework identifies a set of terrain factors that, in her clinical model, either support or resist cancer's ability to grow and spread. While her specific list has been refined across editions and talks, it generally centers on:
- Blood sugar and insulin dysregulation — directly tied to the Warburg effect and the glucose-dependence of cancer cell metabolism.
- Chronic inflammation — a well-established contributor to cancer initiation and progression across mainstream and integrative oncology alike.
- Immune system dysfunction — the body's surveillance and clearance of abnormal cells.
- Microbiome imbalance — gut and broader microbial health, an increasingly researched area even in conventional oncology.
- Toxic burden — environmental and internal toxin exposure and detoxification capacity.
- Mitochondrial dysfunction — the direct through-line back to Seyfried's core thesis.
- Hormonal imbalances, psychospiritual/stress factors, and structural or digestive dysfunction round out the remaining terrain factors in her model.
"Fixing the terrain," in this framework, means systematically assessing and addressing each of these factors — through diet (often ketogenic or modified ketogenic approaches, aimed at reducing the glucose availability cancer cells depend on), targeted lab testing, stress and nervous system regulation, sleep, environmental toxin reduction, and individualized supplementation — alongside, not instead of, conventional treatment.
An Honest Look at the Evidence
I want to be as direct here as I've tried to be throughout this series. The ketogenic and metabolic-therapy approach to cancer has genuine, published, peer-reviewed research behind it — including small human trials, particularly in glioblastoma and some other cancers, generally used as an adjunct to standard treatment, not a replacement for it. The results so far are promising enough to justify continued research, but nowhere near sufficient to be called an established, first-line cancer treatment. Most of the terrain-factor framework itself — the full ten-factor model, specifically — is clinical and theoretical, built from Winters' extensive practice experience and existing research on each individual factor, rather than validated as a complete, unified protocol in large controlled trials.
That doesn't make it worthless. Several of the individual terrain factors — blood sugar control, chronic inflammation, gut health, sleep, and stress — already have strong independent evidence bases in general oncology and chronic disease research, entirely apart from the broader metabolic theory. What's more novel, and less proven, is the specific claim that addressing all of them together, as a unified terrain-based strategy, meaningfully changes cancer outcomes.
Where This Leaves Us
This is a genuinely serious, well-researched body of work, anchored by a real academic researcher in Seyfried and a clinically experienced practitioner in Winters — not fringe material. But it sits at a real edge of current oncology consensus, and it's worth reading and discussing with that context intact: a compelling, still-developing theory with real supporting threads, not a settled alternative to conventional cancer treatment. If any of this is something you or a loved one is considering incorporating alongside treatment, it belongs in a direct conversation with your oncology team, not a decision made from a book alone.
"I know that I know nothing." — Socrates